Director and Former President and Chief Executive Officer · Travere Therapeutics, Inc. (TVTX)

Stephen Aselage

A named executive officer of Travere Therapeutics in every fiscal year CompBrief holds from FY2016 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$1,039,269

Salary $76,151Stock awards $0

FY2018: $4,602,287

7th of 7 named executive officers at Travere Therapeutics by FY2019 total.

7 named officers on file for Travere Therapeutics, FY2019

Stephen Aselage’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • TVTX’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Travere Therapeutics’s whole pay program stands against its peers

  • Travere Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TVTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 14, 2020 (DEF 14A).

Free

Get Stephen Aselage’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Stephen Aselage compensation by year

Travere Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Travere Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019
Salary$510,417$552,570$593,333$76,151
Bonus$0$0$0$0
Stock awards$649,200$795,000$1,312,844$0
Option awards$1,567,712$1,845,855$2,356,660$0
Non-equity incentive$263,415$226,800$331,200$0
Pension and deferred compensation$0$0$0$0
All other$7,950$8,100$8,250$963,118
Total$2,998,694$3,428,325$4,602,287$1,039,269

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Travere Therapeutics, Inc. DEF 14A filed April 14, 2020, accession 0001438533-20-000007, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Travere Therapeutics, Inc. filed document, accession 0001438533-20-000007. Every figure is read from that document and cited to the page and table it appears in. Filed April 14, 2020.

$3.0M
$3.4M
$4.6M
$1.0M
FY16
FY17
FY18
FY19
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
PSU40,000$568,000—
PSU20,625$292,875—
PSU18,500$262,700—
PSU18,375$260,925—
PSU12,250$173,950—
PSU2,000$28,400—
Option8,000—$17.94
Option61,875—$17.44
Option88,813—$25.25

Per the Outstanding Equity Awards at Fiscal Year-End table in Travere Therapeutics, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Travere Therapeutics’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Eric DubePresident, Chief Executive Officer and Director$9,679,319
Noah RosenbergFormer Chief Medical Officer$1,369,643
Peter HeermaChief Commercial Officer$1,325,278
William RoteSenior Vice President and Head of Research and Development$1,310,226
Laura ClagueSenior Vice President and Chief Financial Officer$1,303,582
Elizabeth ReedSenior Vice President, General Counsel and Corporate Secretary$1,258,447
Stephen Aselage · this pageDirector and Former President and Chief Executive Officer$1,039,269

Board service

Travere Therapeutics board · FY2021–FY2022
Director compensation in US dollars, as Travere Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2022$41,250$3,200,000$0—$3,241,250
FY2021$55,000$54,810$164,430—$274,240

Each year as the company reported it in Travere Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Travere Therapeutics pays directors a $50,000 cash retainer. As stated in Travere Therapeutics's FY2022 proxy.

The full Travere Therapeutics compensation record

free company brief

This page is one person within Travere Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Travere Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Stephen Aselage's compensation dossier · One-time report. No refunds.